Availability of generic medicines under PMBJKs

1. At a Glance

• Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) is a Department of Pharmaceuticals scheme that retails quality generic medicines at 50%-80% cheaper than branded equivalents through Jan Aushadhi Kendras (JAKs) [S1][S2].
• Product basket: 2,110 medicines + 315 surgicals/consumables/devices across all major therapeutic groups (cardio, anti-cancer, anti-diabetic, anti-infectives, anti-allergic, GI, nutraceuticals) [S1].
• Implementing agency: Pharmaceuticals & Medical Devices Bureau of India (PMBI) — an autonomous society under Dept of Pharmaceuticals, Ministry of Chemicals & Fertilizers [S4].
• Relevance: GS-II (health, vulnerable sections), GS-III (pharma sector, IPR/generics).

2. Why in the News

• PIB release dated 17 March 2026 (Dept of Pharmaceuticals) reaffirming product-basket size and awareness push [S1].
• Jan Aushadhi Diwas 2025 week-long celebrations flagged off by Union Minister J.P. Nadda in March 2025 [S3].
• Kendra count crossed 17,990 by 31 Dec 2025, up from 15,057 (28 Feb 2025) and 16,912 (30 June 2025) — rapid scale-up toward the 2027 target [S2].

3. Background & Evolution

• Launched November 2008 by Department of Pharmaceuticals as Jan Aushadhi Campaign; rebranded PMBJP in 2015–16 [S4].
• Implementing body reorganised — BPPI (Bureau of Pharma PSUs of India) renamed PMBI (Pharmaceuticals & Medical Devices Bureau of India) [S4].
• Milestones: 9,000+ stores covering 743/766 districts (2022) → 15,057 (Feb 2025) → 17,990 (Dec 2025) [S2][S4].
• Cumulative citizen savings: ~₹23,000 cr in first 9 yrs; ~₹38,000 cr by June 2025 on MRP-equivalent sales of ₹7,700 cr [S4].

4. Core Static Facts

• Scheme: Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) [S1].
• Outlets: Jan Aushadhi Kendras (JAKs) [S1].
• Nodal Ministry: Ministry of Chemicals & Fertilizers — Department of Pharmaceuticals [S1].
• Implementing Agency: PMBI (autonomous society under DoP) [S4].
• Launch year: 2008 (relaunched/rebranded 2015) [S4].
• Product basket: 2,110 drugs + 315 surgicals/consumables/devices [S1].
• Price discount: 50%-80% vs branded [S1].
• Kendras (31 Dec 2025): 17,990 [S2].
• Target: 25,000 JAKs by March 2027 [S2].
• Cumulative savings: ~₹38,000 cr (till June 2025) [S4].

5. Multi-Dimensional Analysis

Economic - Reduces out-of-pocket health expenditure (~62% of total health spend in India) by substituting high-margin branded drugs with generics [S1][S4]. - Cumulative consumer savings ~₹38,000 cr against ₹7,700 cr in MRP sales — a ~5x multiplier on consumer surplus [S4].

Social - Targets affordability for BPL, elderly, chronic-disease patients (diabetes, CVD, cancer) — therapeutic groups explicitly covered [S1]. - Self-employment for pharmacists, SC/ST/Divyangjan, women entrepreneurs via preferential kendra allotment policies [S4].

Administrative / Governance - Quality assured: every batch tested at NABL-accredited labs before supply to Kendras [S1]. - Awareness via IEC campaigns and Jan Aushadhi Diwas (7 March) annually [S3]. - Bottleneck: physician prescription bias toward branded drugs; uneven district-level kendra density.

Scientific / Technological - Leverages India's status as global generics hub ("pharmacy of the world"); aligns with Indian Pharmacopoeia standards [S4].

6. Recent Developments (last 12-18 months)

• March 2025: J.P. Nadda flags off Jan Aushadhi Diwas 2025 celebrations [S3].
• Feb 2025: 15,057 JAKs operational [S2].
• June 2025: 16,912 JAKs; cumulative savings ~₹38,000 cr [S2][S4].
• Dec 2025: 17,990 JAKs [S2].
• March 2026 (PIB): Product basket reaffirmed at 2,110 drugs + 315 surgicals; awareness drives ongoing [S1].

7. Prelims Hooks

• PMBJP launched in November 2008 under Dept of Pharmaceuticals [S4].
• Implementing agency: PMBI (not NPPA, not CDSCO) [S4].
• Parent Ministry: Chemicals & Fertilizers (NOT Health & Family Welfare) [S1].
• Outlets called Jan Aushadhi Kendras (JAKs) [S1].
• Product basket: 2,110 medicines + 315 surgicals/devices [S1].
• Price cut vs branded: 50%-80% [S1].
• Jan Aushadhi Diwas observed annually on 7 March [S3].
• Target: 25,000 JAKs by March 2027 [S2].
• Kendras as on 31 Dec 2025: 17,990 [S2].
• Cumulative savings to citizens (till June 2025): ~₹38,000 crore [S4].
• Quality testing at NABL-accredited labs [S1].
• PMBI is an autonomous society, not a PSU [S4].

8. Mains Relevance

• GS-II: Government policies & interventions for development in health sector; issues relating to poverty & hunger; vulnerable sections.
• GS-III: Indian economy — pharmaceutical sector, IPR & generics.
• Question stems: 1. "PMBJP has democratised access to medicines but acceptance remains the binding constraint." Examine. 2. Discuss the role of generic medicines in reducing out-of-pocket health expenditure in India, with reference to PMBJP. 3. Critically evaluate the institutional design of PMBI in delivering affordable healthcare under PMBJP.

9. Related Topics to Study Next

• Ayushman Bharat (PM-JAY) — complementary financial protection for hospitalisation.
• National Pharmaceutical Pricing Authority (NPPA) & DPCO 2013 — price control on essential drugs.
• National List of Essential Medicines (NLEM) 2022 — basis for price regulation overlap with PMBJP basket.
• Production Linked Incentive (PLI) for Pharma & Bulk Drugs — supply-side support to APIs/KSMs.
• TRIPS & Indian Patents Act 1970 (Sec 3(d)) — generics policy & evergreening jurisprudence.
• Out-of-Pocket Expenditure & National Health Accounts — measures health affordability outcomes.
• CDSCO / Drugs & Cosmetics Act, 1940 — regulatory backbone for drug quality.
• Indian Pharmacopoeia Commission — quality standards for PMBJP procurement.

10. Common Errors / Trap Areas

• Wrong Ministry: PMBJP is under Chemicals & Fertilizers (Dept of Pharmaceuticals), NOT Ministry of Health & Family Welfare [S1].
• Wrong agency: PMBI implements it — not NPPA (pricing), not CDSCO (regulation), not BPPI (old name) [S4].
• Confusing with AMRIT (Affordable Medicines & Reliable Implants for Treatment) — a separate scheme run by HLL Lifecare under MoHFW.
• Launch year: Original launch 2008; rebranded as PMBJP in 2015 — both can appear as decoys.
• Discount band: 50%-80% (not "up to 90%"; not "at cost") [S1].
• Jan Aushadhi Diwas date: 7 March, not 1 March or 7 April [S3].

11. Sources

• [S1] Availability of generic medicines under PMBJKs — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2241166 — (tier 1)
• [S2] 16,912 JAKs opened till 30.6.2025; target 25,000 by March 2027 — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2149782 — (tier 1)
• [S3] J.P. Nadda inaugurates Jan Aushadhi Diwas 2025 — https://www.pib.gov.in/PressReleseDetailm.aspx?PRID=2107206 — (tier 1)
• [S4] PMBJP Backgrounder & PMBI implementing agency, savings data — https://static.pib.gov.in/WriteReadData/specificdocs/documents/2023/mar/doc202337167101.pdf — (tier 1)